Eisai's eribulin misses the capecitabine mark in second-line breast cancer
This article was originally published in Scrip
Executive Summary
After an initial 3.3% drop, shares in Eisai closed down by 1.0% in Tokyo on 10 July as the company disclosed that Halaven (eribulin) missed both primary survival endpoints in a comparative Phase III trial as a second-line therapy for advanced breast cancer.